# QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride

Source: https://onco.cc/trials/nct07601178/  
OnCo record `nct07601178` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of anlotinib and nab-paclitaxel in triple-negative breast cancer, run by Jiangsu Cancer Institute & Hospital, now recruiting.

## Summary

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07601178 by Jiangsu Cancer Institute & Hospital, with a registry enrolment figure of 34 participants, started 2026-04-17 and due to reach its primary completion in 2027-09-15. Interventions recorded: TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Confirmed by histopathological examination as advanced triple-negative invasive breast cancer, meeting the following criteria: pathological type triple-negative, specifically: ER negative (IHC \<1%), PR negative (IHC \<1%), HER2 negative (IHC -/+ or IHC ++ but FISH/CISH negative)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07601178
- Phase: 2
- Setting: QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
- Sponsor: Jiangsu Cancer Institute & Hospital
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT07601178: https://clinicaltrials.gov/study/NCT07601178

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07601178.json